NCT03093922 : Clinical Trial Detail - Cancer Knowledgebase (CKB)

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

NCT ID	NCT03093922
Title	A Study of Two Dosing Schedules of Atezolizumab in Combination With Gemcitabine and Cisplatin as First-Line Treatment for Metastatic Bladder Cancer
Recruitment	Active, not recruiting
Gender	both
Phase	Phase II
Variant Requirements	No
Sponsors	Memorial Sloan Kettering Cancer Center
Indications	urethra transitional cell carcinoma ureter transitional cell carcinoma bladder urothelial carcinoma renal pelvis transitional cell carcinoma
Therapies	Atezolizumab + Cisplatin + Gemcitabine
Age Groups:	senior \| adult
Covered Countries	USA

Filter rows:

Showing 1 to 9 of 9 entries

Facility	City	State	Zip	Country	Details
Memorial Sloan Kettering Basking Ridge (Limited Protocol Activities)	Basking Ridge	New Jersey	07920	United States	Details
Memorial Sloan Kettering Bergen	Montvale	New Jersey	07645	United States	Details
Memorial Sloan Kettering Cancer Center (All Protocol Activities)	New York	New York	10065	United States	Details
Memorial Sloan Kettering Commack (Limited Protocol Activities)	Commack	New York	11725	United States	Details
Memorial Sloan Kettering Monmouth (Limited Protocol Activities)	Middletown	New Jersey	07748	United States	Details
Memorial Sloan Kettering Nassau (Limited Protocol Activities)	Uniondale	New York	11553	United States	Details
Memorial Sloan Kettering Westchester (Limited Protocol Activities)	Harrison	New York	10604	United States	Details
Ohio State University	Columbus	Ohio	43210	United States	Details
University of Chicago	Chicago	Illinois	60637	United States	Details

Showing 1 to 9 of 9 entries

Filter rows:

*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field

NCT03093922Clinical Trial Detail